D. Herbert Opi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
D. Herbert Opi has a total of 149 co-authors. Here are the top co-authors by number of shared publications:
- James G. Beeson
Life Sciences, Burnet Institute, Melbourne, Australia
10 shared publications - Lee Ming Yeoh
Burnet Institute
5 shared publications Linda Reiling
Burnet Institute, 85 Commercial Road, Melbourne, VIC 3004, Australia
5 shared publications- Dominic P. Kwiatkowski
Wellcome Sanger Institute
3 shared publications Ivo Mueller
Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia; Department of Medical Biology, University of Melbourne, Melbourne, VIC, Australia
3 shared publicationsAgnes Orban
Malaria Research Unit, Institut Pasteur du Cambodge, Phnom Penh, Cambodia
2 shared publications
Latest Publications
- Open Access
Hierarchy of immunogenicity of Plasmodium falciparum merozoite antigens and vaccine candidates in first human infection
Background: Merozoite antigens are targets of acquired immunity and are promising targets for next-generation malaria vaccines and serosurveillance tools. However, the immunogenicity of each antigen and their induction of antibodies following infection remains unclear, impacting vaccine design, antigen selection in serosurveillance, and our understanding of naturally-acquired immunity. Methods: To address this, we assessed IgG and IgM responses to whole merozoites and individual merozoite antigens in 81 malaria-naïve adults who experienced a blood-stage P. falciparum Controlled Human Malaria Infection (CHMI). Results: Significant acquisition of IgG and IgM against whole merozoites could be detected as early as two weeks after infection. For IgG responses, a strong hierarchy of immunogenicity among merozoite antigens was observed, with several prominent antigen targets. In contrast, IgM was acquired to most antigens and was less hierarchical with a broader and less antigen-dominant acquisition profile. Participants clustered into distinct immune-acquisition groups according to the breadth and magnitude of their antibody responses, suggesting that individual variation in the development of malaria immunity begins as early as first exposure. Conclusions: Our findings provide important insights into the immunogenicity of merozoite antigens under consideration for vaccine development and identify antigens that could be used in the development of malaria sero-surveillance tools.
Open AccessHierarchy of immunogenicity of Plasmodium falciparum merozoite antigens and vaccine candidates in first human infection
Background: Merozoite antigens are targets of acquired immunity and are promising targets for next-generation malaria vaccines and serosurveillance tools. However, the immunogenicity of each antigen and their induction of antibodies following infection remains unclear, impacting vaccine design, antigen selection in serosurveillance, and our understanding of naturally-acquired immunity. Methods: To address this, we assessed IgG and IgM responses to whole merozoites and individual merozoite antigens in 81 malaria-naïve adults who experienced a blood-stage P. falciparum Controlled Human Malaria Infection (CHMI). Results: Significant acquisition of IgG and IgM against whole merozoites could be detected as early as two weeks after infection. For IgG responses, a strong hierarchy of immunogenicity among merozoite antigens was observed, with several prominent antigen targets. In contrast, IgM was acquired to most antigens and was less hierarchical with a broader and less antigen-dominant acquisition profile. Participants clustered into distinct immune-acquisition groups according to the breadth and magnitude of their antibody responses, suggesting that individual variation in the development of malaria immunity begins as early as first exposure. Conclusions: Our findings provide important insights into the immunogenicity of merozoite antigens under consideration for vaccine development and identify antigens that could be used in the development of malaria sero-surveillance tools.
- Top Cited PapersOpen Access
A longitudinal study of children identifies antibody Fc-mediated functions and antigen targets of immunity to Plasmodium vivax malaria
- Open Access
- 19 December 2024
- Published by Springer Nature in Communications Medicine
- Vol. 4 (1) , 1-13
Induction of Fc-dependent functional antibodies against different variants of SARS-CoV-2 varies by vaccine type and prior infection
Background SARS-CoV-2 transmission and COVID-19 disease severity is influenced by immunity from natural infection and/or vaccination. Population-level immunity is complicated by the emergence of viral variants. Antibody Fc-dependent effector functions are as important mediators in immunity. However, their induction in populations with diverse infection and/or vaccination histories and against variants remains poorly defined. Methods We evaluated Fc-dependent functional antibodies following vaccination with two widely used vaccines, AstraZeneca (AZ) and Sinovac (SV), including antibody binding of Fcγ-receptors and complement-fixation in vaccinated Brazilian adults (n = 222), some of who were previously infected with SARS-CoV-2, as well as adults with natural infection only (n = 200). IgG, IgM, IgA, and IgG subclasses were also quantified. Results AZ induces greater Fcγ-receptor-binding (types I, IIa, and IIIa/b) antibodies than SV or natural infection. Previously infected individuals have significantly greater vaccine-induced responses compared to naïve counterparts. Fcγ-receptor-binding is highest among AZ vaccinated individuals with a prior infection, for all receptor types, and substantial complement-fixing activity is only seen among this group. SV induces higher IgM than AZ, but this does not drive better complement-fixing activity. Some SV responses are associated with subject age, whereas AZ responses are not. Importantly, functional antibody responses are well retained against the Omicron BA.1 S protein, being best retained for Fcγ-receptor-1 binding, and are higher for AZ than SV. Conclusions Hybrid immunity, from combined natural exposure and vaccination, generates strong Fc-mediated antibody functions which may contribute to immunity against evolving SARS-CoV-2 variants. Understanding determinants of Fc-mediated functions may enable future vaccines with greater efficacy against different variants.
- 19 December 2024
- Published by Springer Nature in Communications Medicine
- Vol. 4 (1) , 1-13
Open AccessInduction of Fc-dependent functional antibodies against different variants of SARS-CoV-2 varies by vaccine type and prior infection
Background SARS-CoV-2 transmission and COVID-19 disease severity is influenced by immunity from natural infection and/or vaccination. Population-level immunity is complicated by the emergence of viral variants. Antibody Fc-dependent effector functions are as important mediators in immunity. However, their induction in populations with diverse infection and/or vaccination histories and against variants remains poorly defined. Methods We evaluated Fc-dependent functional antibodies following vaccination with two widely used vaccines, AstraZeneca (AZ) and Sinovac (SV), including antibody binding of Fcγ-receptors and complement-fixation in vaccinated Brazilian adults (n = 222), some of who were previously infected with SARS-CoV-2, as well as adults with natural infection only (n = 200). IgG, IgM, IgA, and IgG subclasses were also quantified. Results AZ induces greater Fcγ-receptor-binding (types I, IIa, and IIIa/b) antibodies than SV or natural infection. Previously infected individuals have significantly greater vaccine-induced responses compared to naïve counterparts. Fcγ-receptor-binding is highest among AZ vaccinated individuals with a prior infection, for all receptor types, and substantial complement-fixing activity is only seen among this group. SV induces higher IgM than AZ, but this does not drive better complement-fixing activity. Some SV responses are associated with subject age, whereas AZ responses are not. Importantly, functional antibody responses are well retained against the Omicron BA.1 S protein, being best retained for Fcγ-receptor-1 binding, and are higher for AZ than SV. Conclusions Hybrid immunity, from combined natural exposure and vaccination, generates strong Fc-mediated antibody functions which may contribute to immunity against evolving SARS-CoV-2 variants. Understanding determinants of Fc-mediated functions may enable future vaccines with greater efficacy against different variants.
- Open Access
- 4 December 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-16
Potent AMA1-specific human monoclonal antibody against Plasmodium vivax Pre-erythrocytic and Blood Stages
New therapeutics are necessary for preventing Plasmodium vivax malaria due to easy transmissibility and dormancy in the liver that increases the clinical burden due to recurrent relapse. In this manuscript we characterize 12 Pv Apical Membrane Antigen 1 (PvAMA1) specific human monoclonal antibodies from Peripheral Blood Mononuclear Cells of a Pv-exposed individual. PvAMA1 is essential for sporozoite and merozoite invasion, making it a unique therapeutic target. We show that humAb 826827 blocks the invasion of human reticulocytes using Pv clinical isolates and inhibits sporozoite invasion of human hepatocytes in vitro (IC50 of 0.3 – 3.7 µg/mL). Inoculation of human liver transgenic (FRG-humHep) female mice with humAb 826827 significantly reduces liver infection in vivo. The crystal structure of rPvAMA1 bound to 826827 shows that 826827 partially occupies the highly conserved hydrophobic groove in PvAMA1 that binds its known receptor, RON2. We have isolated a potent humAb that is isolate-transcendent, blocks both pre-erythrocytic and blood stage infection, and could be a potential therapy for Pv.
- 4 December 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-16
Open AccessPotent AMA1-specific human monoclonal antibody against Plasmodium vivax Pre-erythrocytic and Blood Stages
New therapeutics are necessary for preventing Plasmodium vivax malaria due to easy transmissibility and dormancy in the liver that increases the clinical burden due to recurrent relapse. In this manuscript we characterize 12 Pv Apical Membrane Antigen 1 (PvAMA1) specific human monoclonal antibodies from Peripheral Blood Mononuclear Cells of a Pv-exposed individual. PvAMA1 is essential for sporozoite and merozoite invasion, making it a unique therapeutic target. We show that humAb 826827 blocks the invasion of human reticulocytes using Pv clinical isolates and inhibits sporozoite invasion of human hepatocytes in vitro (IC50 of 0.3 – 3.7 µg/mL). Inoculation of human liver transgenic (FRG-humHep) female mice with humAb 826827 significantly reduces liver infection in vivo. The crystal structure of rPvAMA1 bound to 826827 shows that 826827 partially occupies the highly conserved hydrophobic groove in PvAMA1 that binds its known receptor, RON2. We have isolated a potent humAb that is isolate-transcendent, blocks both pre-erythrocytic and blood stage infection, and could be a potential therapy for Pv.
- Open Access
- 22 August 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-17
A broadly cross-reactive i-body to AMA1 potently inhibits blood and liver stages of Plasmodium parasites
Apical membrane antigen-1 (AMA1) is a conserved malarial vaccine candidate essential for the formation of tight junctions with the rhoptry neck protein (RON) complex, enabling Plasmodium parasites to invade human erythrocytes, hepatocytes, and mosquito salivary glands. Despite its critical role, extensive surface polymorphisms in AMA1 have led to strain-specific protection, limiting the success of AMA1-based interventions beyond initial clinical trials. Here, we identify an i-body, a humanised single-domain antibody-like molecule that recognises a conserved pan-species conformational epitope in AMA1 with low nanomolar affinity and inhibits the binding of the RON2 ligand to AMA1. Structural characterisation indicates that the WD34 i-body epitope spans the centre of the conserved hydrophobic cleft in AMA1, where interacting residues are highly conserved among all Plasmodium species. Furthermore, we show that WD34 inhibits merozoite invasion of erythrocytes by multiple Plasmodium species and hepatocyte invasion by P. falciparum sporozoites. Despite a short half-life in mouse serum, we demonstrate that WD34 transiently suppressed P. berghei infections in female BALB/c mice. Our work describes the first pan-species AMA1 biologic with inhibitory activity against multiple life-cycle stages of Plasmodium. With improved pharmacokinetic characteristics, WD34 could be a potential immunotherapy against multiple species of Plasmodium.
- 22 August 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-17
Open AccessA broadly cross-reactive i-body to AMA1 potently inhibits blood and liver stages of Plasmodium parasites
Apical membrane antigen-1 (AMA1) is a conserved malarial vaccine candidate essential for the formation of tight junctions with the rhoptry neck protein (RON) complex, enabling Plasmodium parasites to invade human erythrocytes, hepatocytes, and mosquito salivary glands. Despite its critical role, extensive surface polymorphisms in AMA1 have led to strain-specific protection, limiting the success of AMA1-based interventions beyond initial clinical trials. Here, we identify an i-body, a humanised single-domain antibody-like molecule that recognises a conserved pan-species conformational epitope in AMA1 with low nanomolar affinity and inhibits the binding of the RON2 ligand to AMA1. Structural characterisation indicates that the WD34 i-body epitope spans the centre of the conserved hydrophobic cleft in AMA1, where interacting residues are highly conserved among all Plasmodium species. Furthermore, we show that WD34 inhibits merozoite invasion of erythrocytes by multiple Plasmodium species and hepatocyte invasion by P. falciparum sporozoites. Despite a short half-life in mouse serum, we demonstrate that WD34 transiently suppressed P. berghei infections in female BALB/c mice. Our work describes the first pan-species AMA1 biologic with inhibitory activity against multiple life-cycle stages of Plasmodium. With improved pharmacokinetic characteristics, WD34 could be a potential immunotherapy against multiple species of Plasmodium.
- Open Access
- 8 February 2024
- Published by Springer Nature in Research Square
Potent AMA1-specific human monoclonal antibody against P. vivax Pre-erythrocytic and Blood Stages
New therapeutics are a priority for preventing and eliminating Plasmodium vivax (Pv) malaria because of its easy transmissibility and dormant stages in the liver. Relapses due to the dormant liver stages are the major contributor to reoccurring Pv. Therefore, therapies that reduce the establishment of dormant parasites and blood-stage infection are important for controlling this geographically widespread parasite. Here, we isolated 12 human monoclonal antibodies (humAbs) from the plasma of a Pv-exposed individual that recognized Pv apical membrane antigen 1 (PvAMA1). PvAMA1 is important for both sporozoite invasion of hepatocytes and merozoite invasion of reticulocytes. We identified one humAb, 826827, that blocked invasion of human erythrocytes using a transgenic P. falciparum line expressing PvAMA1 (IC50 = 3 µg/mL) and all Pv clinical isolates in vitro. This humAb also inhibited sporozoite invasion of a human hepatocyte cell line and primary human hepatocytes (IC50 of 0.3 – 3.7 µg/mL). The crystal structure of recombinant PvAMA1 with the antigen-binding fragment of 826827 at 2.4 Å resolution shows that the humAb partially occupies the highly conserved hydrophobic groove in PvAMA1 that binds its known receptor, RON2. HumAb 826827 binds to PvAMA1 with higher affinity than RON2, accounting for its potency. To our knowledge, this is the first reported humAb specific to PvAMA1, and the PvAMA1 residues it binds to are highly conserved across different isolates, explaining its strain-transcendent properties.
- 8 February 2024
- Published by Springer Nature in Research Square
Open AccessPotent AMA1-specific human monoclonal antibody against P. vivax Pre-erythrocytic and Blood Stages
New therapeutics are a priority for preventing and eliminating Plasmodium vivax (Pv) malaria because of its easy transmissibility and dormant stages in the liver. Relapses due to the dormant liver stages are the major contributor to reoccurring Pv. Therefore, therapies that reduce the establishment of dormant parasites and blood-stage infection are important for controlling this geographically widespread parasite. Here, we isolated 12 human monoclonal antibodies (humAbs) from the plasma of a Pv-exposed individual that recognized Pv apical membrane antigen 1 (PvAMA1). PvAMA1 is important for both sporozoite invasion of hepatocytes and merozoite invasion of reticulocytes. We identified one humAb, 826827, that blocked invasion of human erythrocytes using a transgenic P. falciparum line expressing PvAMA1 (IC50 = 3 µg/mL) and all Pv clinical isolates in vitro. This humAb also inhibited sporozoite invasion of a human hepatocyte cell line and primary human hepatocytes (IC50 of 0.3 – 3.7 µg/mL). The crystal structure of recombinant PvAMA1 with the antigen-binding fragment of 826827 at 2.4 Å resolution shows that the humAb partially occupies the highly conserved hydrophobic groove in PvAMA1 that binds its known receptor, RON2. HumAb 826827 binds to PvAMA1 with higher affinity than RON2, accounting for its potency. To our knowledge, this is the first reported humAb specific to PvAMA1, and the PvAMA1 residues it binds to are highly conserved across different isolates, explaining its strain-transcendent properties.
- Open Access
- 18 December 2023
- Published by Springer Nature in Research Square
A broadly cross-reactive i-body to AMA1 potently inhibits blood and liver stages of Plasmodium parasites
Broadly cross-reactive anti-malarial vaccines and therapeutic interventions are needed to achieve better outcomes in controlling and, eventually, eradicating malaria. Apical membrane antigen-1 (AMA1) is a structurally and functionally conserved malarial vaccine candidate involved in the tight junction formation with the rhoptry neck protein (RON) complex at the host cell-parasite interface. This interaction is crucial for all Plasmodium parasites to invade human erythrocytes, hepatocytes and mosquito salivary glands effectively. However, extensive surface polymorphisms have induced P. falciparum strain-specific protection which has so far hindered the progression of AMA1-based interventions beyond the first clinical trial. Here, we identified a humanised single-domain (i-body) that recognises a conserved pan-species conformational epitope in AMA1 with low nanomolar affinity and inhibits the binding of the RON2 ligand to AMA1. Structural characterisation indicated that the WD34 i-body epitope engages the centre of the conserved hydrophobic cleft in AMA1, where interacting residues are highly conserved among all Plasmodium species and other apicomplexans. Further, we showed that WD34 inhibits merozoite invasion into RBCs by multiple Plasmodium species and hepatocyte invasion by P. falciparum sporozoites. Our work describes the identification of the first pan-species AMA1 biologic with high multi-lifecycle stage invasion inhibitory activity. This work identifies new tools for species-independent immunoprophylaxis and a possible target for structure-based vaccine development against malaria.
- 18 December 2023
- Published by Springer Nature in Research Square
Open AccessA broadly cross-reactive i-body to AMA1 potently inhibits blood and liver stages of Plasmodium parasites
Broadly cross-reactive anti-malarial vaccines and therapeutic interventions are needed to achieve better outcomes in controlling and, eventually, eradicating malaria. Apical membrane antigen-1 (AMA1) is a structurally and functionally conserved malarial vaccine candidate involved in the tight junction formation with the rhoptry neck protein (RON) complex at the host cell-parasite interface. This interaction is crucial for all Plasmodium parasites to invade human erythrocytes, hepatocytes and mosquito salivary glands effectively. However, extensive surface polymorphisms have induced P. falciparum strain-specific protection which has so far hindered the progression of AMA1-based interventions beyond the first clinical trial. Here, we identified a humanised single-domain (i-body) that recognises a conserved pan-species conformational epitope in AMA1 with low nanomolar affinity and inhibits the binding of the RON2 ligand to AMA1. Structural characterisation indicated that the WD34 i-body epitope engages the centre of the conserved hydrophobic cleft in AMA1, where interacting residues are highly conserved among all Plasmodium species and other apicomplexans. Further, we showed that WD34 inhibits merozoite invasion into RBCs by multiple Plasmodium species and hepatocyte invasion by P. falciparum sporozoites. Our work describes the identification of the first pan-species AMA1 biologic with high multi-lifecycle stage invasion inhibitory activity. This work identifies new tools for species-independent immunoprophylaxis and a possible target for structure-based vaccine development against malaria.
- Open Access
- 14 September 2023
- Published by Public Library of Science (PLoS) in PLOS Genetics
- Vol. 19 (9) , e1010910
Non-O ABO blood group genotypes differ in their associations with Plasmodium falciparum rosetting and severe malaria
Blood group O is associated with protection against severe malaria and reduced size and stability of P. falciparum-host red blood cell (RBC) rosettes compared to non-O blood groups. Whether the non-O blood groups encoded by the specific ABO genotypes AO, BO, AA, BB and AB differ in their associations with severe malaria and rosetting is unknown. The A and B antigens are host RBC receptors for rosetting, hence we hypothesized that the higher levels of A and/or B antigen on RBCs from AA, BB and AB genotypes compared to AO/BO genotypes could lead to larger rosettes, increased microvascular obstruction and higher risk of malaria pathology. We used a case-control study of Kenyan children and in vitro adhesion assays to test the hypothesis that “double dose” non-O genotypes (AA, BB, AB) are associated with increased risk of severe malaria and larger rosettes than “single dose” heterozygotes (AO, BO). In the case-control study, compared to OO, the double dose genotypes consistently had higher odds ratios (OR) for severe malaria than single dose genotypes, with AB (OR 1.93) and AO (OR 1.27) showing most marked difference (p = 0.02, Wald test). In vitro experiments with blood group A-preferring P. falciparum parasites showed that significantly larger rosettes were formed with AA and AB host RBCs compared to OO, whereas AO and BO genotypes rosettes were indistinguishable from OO. Overall, the data show that ABO genotype influences P. falciparum rosetting and support the hypothesis that double dose non-O genotypes confer a greater risk of severe malaria than AO/BO heterozygosity.
- 14 September 2023
- Published by Public Library of Science (PLoS) in PLOS Genetics
- Vol. 19 (9) , e1010910
Open AccessNon-O ABO blood group genotypes differ in their associations with Plasmodium falciparum rosetting and severe malaria
Blood group O is associated with protection against severe malaria and reduced size and stability of P. falciparum-host red blood cell (RBC) rosettes compared to non-O blood groups. Whether the non-O blood groups encoded by the specific ABO genotypes AO, BO, AA, BB and AB differ in their associations with severe malaria and rosetting is unknown. The A and B antigens are host RBC receptors for rosetting, hence we hypothesized that the higher levels of A and/or B antigen on RBCs from AA, BB and AB genotypes compared to AO/BO genotypes could lead to larger rosettes, increased microvascular obstruction and higher risk of malaria pathology. We used a case-control study of Kenyan children and in vitro adhesion assays to test the hypothesis that “double dose” non-O genotypes (AA, BB, AB) are associated with increased risk of severe malaria and larger rosettes than “single dose” heterozygotes (AO, BO). In the case-control study, compared to OO, the double dose genotypes consistently had higher odds ratios (OR) for severe malaria than single dose genotypes, with AB (OR 1.93) and AO (OR 1.27) showing most marked difference (p = 0.02, Wald test). In vitro experiments with blood group A-preferring P. falciparum parasites showed that significantly larger rosettes were formed with AA and AB host RBCs compared to OO, whereas AO and BO genotypes rosettes were indistinguishable from OO. Overall, the data show that ABO genotype influences P. falciparum rosetting and support the hypothesis that double dose non-O genotypes confer a greater risk of severe malaria than AO/BO heterozygosity.
- Open Access
Non- O ABO blood group genotypes differ in their associations with Plasmodium falciparum rosetting and severe malaria
Blood group O is associated with protection against severe malaria and reduced size and stability of P. falciparum- host red blood cell (RBC) rosettes compared to non-O blood groups. Whether the non-O blood groups encoded by the specific ABO genotypes AO, BO, AA, BB and AB differ in their associations with severe malaria and rosetting is unknown. The A and B antigens are host RBC receptors for rosetting, hence we hypothesized that the higher levels of A and/or B antigen on RBCs from AA, BB and AB genotypes compared to AO/BO genotypes could lead to larger rosettes, increased microvascular obstruction and higher risk of malaria pathology. We used a case-control study of Kenyan children and in vitro adhesion assays to test the hypothesis that “double dose” non- O genotypes ( AA, BB, AB ) are associated with increased risk of severe malaria and larger rosettes than “single dose” heterozygotes ( AO, BO ). In the case-control study, compared to OO , the double dose genotypes consistently had higher odds ratios (OR) for severe malaria than single dose genotypes, with AB (OR 1.93) and AO (OR 1.27) showing most marked difference (P=0.02, Wald test). In vitro experiments with blood group A-preferring P. falciparum parasites showed that significantly larger rosettes were formed with AA and AB host RBCs compared to OO , whereas AO genotype rosettes were indistinguishable from OO . Overall, the data show that ABO genotype influences P. falciparum rosetting and support the hypothesis that double dose non- O genotypes confer a greater risk of severe malaria than AO/BO heterozygosity.
Open AccessNon- O ABO blood group genotypes differ in their associations with Plasmodium falciparum rosetting and severe malaria
Blood group O is associated with protection against severe malaria and reduced size and stability of P. falciparum- host red blood cell (RBC) rosettes compared to non-O blood groups. Whether the non-O blood groups encoded by the specific ABO genotypes AO, BO, AA, BB and AB differ in their associations with severe malaria and rosetting is unknown. The A and B antigens are host RBC receptors for rosetting, hence we hypothesized that the higher levels of A and/or B antigen on RBCs from AA, BB and AB genotypes compared to AO/BO genotypes could lead to larger rosettes, increased microvascular obstruction and higher risk of malaria pathology. We used a case-control study of Kenyan children and in vitro adhesion assays to test the hypothesis that “double dose” non- O genotypes ( AA, BB, AB ) are associated with increased risk of severe malaria and larger rosettes than “single dose” heterozygotes ( AO, BO ). In the case-control study, compared to OO , the double dose genotypes consistently had higher odds ratios (OR) for severe malaria than single dose genotypes, with AB (OR 1.93) and AO (OR 1.27) showing most marked difference (P=0.02, Wald test). In vitro experiments with blood group A-preferring P. falciparum parasites showed that significantly larger rosettes were formed with AA and AB host RBCs compared to OO , whereas AO genotype rosettes were indistinguishable from OO . Overall, the data show that ABO genotype influences P. falciparum rosetting and support the hypothesis that double dose non- O genotypes confer a greater risk of severe malaria than AO/BO heterozygosity.
- Open Access
- 25 August 2021
- Published by Springer Nature in Communications Medicine
- Vol. 1 (1) , 1-5
Recent clinical trials inform the future for malaria vaccines
Malaria vaccines are urgently needed in the fight against this devastating disease that is responsible for almost half a million deaths each year. Here, we discuss recent clinical advances in vaccine development and highlight ongoing challenges for the future. Kurtovic et al. highlight some of the recent advances in the development and clinical evaluation of malaria vaccines. The authors outline key vaccine strategies and clinical trials, and discuss priorities for research into the development of an efficacious malaria vaccine.
- 25 August 2021
- Published by Springer Nature in Communications Medicine
- Vol. 1 (1) , 1-5
Open AccessRecent clinical trials inform the future for malaria vaccines
Malaria vaccines are urgently needed in the fight against this devastating disease that is responsible for almost half a million deaths each year. Here, we discuss recent clinical advances in vaccine development and highlight ongoing challenges for the future. Kurtovic et al. highlight some of the recent advances in the development and clinical evaluation of malaria vaccines. The authors outline key vaccine strategies and clinical trials, and discuss priorities for research into the development of an efficacious malaria vaccine.